PMID- 27476722
OWN - NLM
STAT- MEDLINE
DCOM- 20170913
LR  - 20220317
IS  - 1523-1747 (Electronic)
IS  - 0022-202X (Linking)
VI  - 136
IP  - 12
DP  - 2016 Dec
TI  - HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the 
      Ustekinumab Phase 3 Psoriasis Program.
PG  - 2364-2371
LID - S0022-202X(16)32230-8 [pii]
LID - 10.1016/j.jid.2016.06.631 [doi]
AB  - Several small studies suggest that the presence of the human leukocyte antigen 
      (HLA)-Cw6 (C*06:02) allele may be a predictor of improved response to 
      ustekinumab. This study was designed to assess the association of the HLA-C*06:02 
      allele with response to ustekinumab in large cohorts of patients from the phase 3 
      studies of ustekinumab in moderate-to-severe psoriasis. In this retrospective 
      study, both HLA-C*06:02-positive and -negative patients demonstrated good 
      responses to ustekinumab (86% vs. 76%, respectively, achieved at least a 75% 
      improvement from baseline in Psoriasis Area and Severity Index [PASI 75] at week 
      24). A modestly higher proportion of HLA-C*06:02-positive than 
      HLA-C*06:02-negative patients achieved PASI 75/90 responses at weeks 12 and 24. 
      The largest response difference between the positive and negative patients 
      (17.9%) was observed for PASI 75 (week 12), with smaller differences noted at 
      later time points for PASI 90 (11.8% at week 24) and PASI 100 (10.2% at week 28). 
      A differential response to ustekinumab has been confirmed in HLA-C*06:02-positive 
      versus HLA-C*06:02-negative patients; however, this difference is modest, 
      particularly at the higher response rate thresholds (PASI 90/100) and later time 
      points (weeks 24/28).
CI  - Copyright (c) 2016 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Li, Katherine
AU  - Li K
AD  - Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
FAU - Huang, C Chris
AU  - Huang CC
AD  - Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
FAU - Randazzo, Bruce
AU  - Randazzo B
AD  - Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
FAU - Li, Shu
AU  - Li S
AD  - Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
FAU - Szapary, Philippe
AU  - Szapary P
AD  - Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
FAU - Curran, Mark
AU  - Curran M
AD  - Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
FAU - Campbell, Kim
AU  - Campbell K
AD  - Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
FAU - Brodmerkel, Carrie
AU  - Brodmerkel C
AD  - Janssen Research & Development, LLC, Spring House, Pennsylvania, USA. Electronic 
      address: CBrodmer@its.jnj.com.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160729
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-C*06 antigen)
RN  - 0 (Interleukin-23)
RN  - FU77B4U5Z0 (Ustekinumab)
SB  - IM
CIN - J Invest Dermatol. 2016 Dec;136(12 ):2339-2340. PMID: 27884289
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Alleles
MH  - Analysis of Variance
MH  - Child
MH  - Confidence Intervals
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - HLA-C Antigens/drug effects/*genetics
MH  - Humans
MH  - Interleukin-23/*antagonists & inhibitors/immunology
MH  - Male
MH  - Molecular Targeted Therapy/methods
MH  - Prognosis
MH  - Psoriasis/*drug therapy/*genetics/immunology
MH  - Risk Assessment
MH  - Sex Factors
MH  - Treatment Outcome
MH  - Ustekinumab/*therapeutic use
MH  - Young Adult
EDAT- 2016/08/02 06:00
MHDA- 2017/09/14 06:00
CRDT- 2016/08/02 06:00
PHST- 2016/04/04 00:00 [received]
PHST- 2016/06/08 00:00 [revised]
PHST- 2016/06/29 00:00 [accepted]
PHST- 2016/08/02 06:00 [pubmed]
PHST- 2017/09/14 06:00 [medline]
PHST- 2016/08/02 06:00 [entrez]
AID - S0022-202X(16)32230-8 [pii]
AID - 10.1016/j.jid.2016.06.631 [doi]
PST - ppublish
SO  - J Invest Dermatol. 2016 Dec;136(12):2364-2371. doi: 10.1016/j.jid.2016.06.631. 
      Epub 2016 Jul 29.